Mart Reimund

Dr. Mart Reimund

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2016 in Chemical Science
Verified
Journal Article
Open access
PDF file
SKSandra Kaabel
Sandra Kaabel
JAJasper Adamson
Jasper Adamson
FTFilip Topic
Filip Topic
AKAnniina Kiesilä
Anniina Kiesilä
EKElina Kalenius
Elina Kalenius
Riina AavRiina Aav
Riina Aav
A novel eight-membered macrocycle of the hemicucurbit[n]uril family, chiral (all-R)-cyclohexanohemicucurbit[8]uril (cycHC[8]) binds anions in a purely protic solvent with remarkable selectivity. The cycHC[8] portals open and close to fully encapsulate anions in a 1 : 1 ratio, resembling a molecular Pac-Man™. Comprehensive gas, solution and solid phase studies prove that the binding is governed by the size, shape and charge distribution of the bound anion. Gas phase studies show an order of SbF6 − ≈ PF6 − > ReO4 − > ClO4 − > SCN− > BF4 − > HSO4 − > CF3SO3 − for anion complexation strength. An extensive crystallographic study reveals the preferred orientations of the anions within the octahedral cavity of cycHC[8] and highlights the importance of the size- and shape-matching between the anion and the receptor cavity. The solution studies show the strongest binding of the ideally fitting SbF6 − anion, with an association constant of 2.5 × 105 M−1 in pure methanol. The symmetric, receptor cavity-matching charge distribution of the anions results in drastically stronger binding than in the case of anions with asymmetric charge distribution. Isothermal titration calorimetry (ITC) reveals the complexation to be exothermic and enthalpy-driven. The DFT calculations and VT-NMR studies confirmed that the complexation proceeds through a pre-complex formation while the exchange of methanol solvent with the anion is the rate-limiting step. The octameric cycHC[8] offers a unique example of template-controlled design of an electroneutral host for binding large anions in a competitive polar solvent.

11 December 2024 in Nature
Verified
Journal Article
Closed access
PDF file
MRMart Reimund
Mart Reimund
ADAltaira D. Dearborn
Altaira D. Dearborn
GGGiorgio Graziano
Giorgio Graziano
HLHaotian Lei
Haotian Lei
ACAnthony M. Ciancone
Anthony M. Ciancone
JMJoseph Marcotrigiano
Joseph Marcotrigiano

8 March 2021 in Cells
Verified
Journal Article
Open access
PDF file
AWAnna Wolska
Anna Wolska
MRMart Reimund
Mart Reimund
DSDenis O. Sviridov
Denis O. Sviridov
MAMarcelo J. Amar
Marcelo J. Amar
ARAlan Remaley
Alan Remaley
Since the seminal breakthrough of treating diabetic patients with insulin in the 1920s, there has been great interest in developing other proteins and their peptide mimetics as therapies for a wide variety of other medical disorders. Currently, there are at least 60 different peptides that have been approved for human use and over 150 peptides that are in various stages of clinical development. Peptides mimetic of the major proteins on lipoproteins, namely apolipoproteins, have also been developed first as tools for understanding apolipoprotein structure and more recently as potential therapeutics. In this review, we discuss the biochemistry, peptide mimetics design and clinical trials for peptides based on apoA-I, apoE and apoC-II. We primarily focus on applications of peptide mimetics related to cardiovascular diseases. We conclude with a discussion on the limitations of peptides as therapeutic agents and the challenges that need to be overcome before apolipoprotein mimetic peptides can be developed into new drugs.

1 January 2017 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
MRMart Reimund
Mart Reimund
OKOleg Kovrov
Oleg Kovrov
GOGunilla Olivecrona
Gunilla Olivecrona
ALAivar Lookene
Aivar Lookene
Lipoprotein lipase (LPL) hydrolyzes triglycerides in plasma lipoproteins. Due to the complex regulation mechanism, it has been difficult to mimic in vitro the physiological conditions under which LPL acts. We demonstrate that isothermal titration calorimetry (ITC), using human plasma as substrate, overcomes several limitations of previously used techniques. The high sensitivity of ITC allows continuous recordings of the heat released during hydrolysis. Both initial rates and kinetics for complete hydrolysis of plasma lipids can be studied. The heat rate was shown to correspond to the release of fatty acids and was linearly related to the amount of added enzyme, either purified LPL or post-heparin plasma. Addition of apoC-III reduced the initial rate of hydrolysis by LPL, but the inhibition became less prominent with time when the lipoproteins were triglyceride-poor. Addition of angiopoietin-like proteins 3 or 4 caused reduction of the activity of LPL via a two-step mechanism. We conclude that ITC can be used for quantitative measurements of LPL activity and interactions under in vivo-like conditions, for comparisons of the properties of plasma samples from patients and control subjects as substrates for LPL, as well as for testing of drug candidates developed with the aim to affect the LPL system.

1 May 2015 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MRMart Reimund
Mart Reimund
MLMikael Larsson
Mikael Larsson
OKOleg Kovrov
Oleg Kovrov
SKSergo Kasvandik
Sergo Kasvandik
GOGunilla Olivecrona
Gunilla Olivecrona
ALAivar Lookene
Aivar Lookene
GPIHBP1 is an endothelial membrane protein that transports lipoprotein lipase (LPL) from the subendothelial space to the luminal side of the capillary endothelium. Here, we provide evidence that two regions of GPIHBP1, the acidic N-terminal domain and the central Ly6 domain, interact with LPL as two distinct binding sites. This conclusion is based on comparative binding studies performed with a peptide corresponding to the N-terminal domain of GPIHBP1, the Ly6 domain of GPIHBP1, wild type GPIHBP1, and the Ly6 domain mutant GPIHBP1 Q114P. Although LPL and the N-terminal domain formed a tight but short lived complex, characterized by fast on-and off-rates, the complex between LPL and the Ly6 domain formed more slowly and persisted for a longer time. Unlike the interaction of LPL with the Ly6 domain, the interaction of LPL with the N-terminal domain was significantly weakened by salt. The Q114P mutant bound LPL similarly to the N-terminal domain of GPIHBP1. Heparin dissociated LPL from the N-terminal domain, and partially from wild type GPIHBP1, but was unable to elute the enzyme from the Ly6 domain. When LPL was in complex with the acidic peptide corresponding to the N-terminal domain of GPIHBP1, the enzyme retained its affinity for the Ly6 domain. Furthermore, LPL that was bound to the N-terminal domain interacted with lipoproteins, whereas LPL bound to the Ly6 domain did not. In summary, our data suggest that the two domains of GPIHBP1 interact independently with LPL and that the functionality of LPL depends on its localization on GPIHBP1.

23 May 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
ASAlexander V. Sorokin
Alexander V. Sorokin
NPNidhi Patel
Nidhi Patel
KAKhaled Abdelrahman
Khaled Abdelrahman
CLClarence Ling
Clarence Ling
MRMart Reimund
Mart Reimund
ARAlan T. Remaley
Alan T. Remaley
Background: Although traditional lipid parameters and coronary imaging techniques are valuable for cardiovascular disease (CVD) risk prediction, better diagnostic tests are still needed. Methods: In a prospective, observational study, 795 individuals had extensive cardiometabolic profiling, including emerging biomarkers, such as apolipoprotein E–containing HDL-cholesterol (ApoE-HDL-C). Coronary artery calcium (CAC) score was assessed in the entire cohort, and quantitative coronary computed tomography angiography (CCTA) characterization of total burden, noncalcified burden (NCB), and fibrous plaque burden (FB) was performed in a subcohort ( n = 300) of patients stratified by concentration of ApoE-HDL-C. Total and HDL-containing apolipoprotein C-III (ApoC-III) were also measured. Results: Most patients had a clinical diagnosis of coronary artery disease (CAD) ( n = 80.4% of 795), with mean age of 59 years, a majority being male (57%), and about half on statin treatment. The low ApoE-HDL-C group had more severe stenosis (11% vs. 2%, overall P < 0.001), with higher CAC as compared with high ApoE-HDL-C. On quantitative CCTA, the high ApoE-HDL-C group had lower NCB (β = –0.24, P = 0.0001), which tended to be significant in a fully adjusted model (β = –0.32, P = 0.001) and altered by ApoC-III in HDL levels. Low ApoE-HDL-C was significantly associated with LDL particle number (β = 0.31; P = 0.0001). Finally, when stratified by FB, ApoC-III in HDL showed a more robust predictive value of CAD over ApoE-HDL-C (AUC: 0.705, P = 0.0001) in a fully adjusted model. Conclusion: ApoE-containing HDL-C showed a significant association with early coronary plaque characteristics and is affected by the presence of ApoC-III, indicating that low ApoE-HDL-C and high ApoC-III may be important markers of CVD severity. Trial Registration: ClinicalTrials.gov: NCT01621594. Funding: This work was supported by the NHLBI at the NIH Intramural Research Program.